Is eligibility for a chemotherapy protocol a good prognostic factor for invasive bladder cancer after radical cystectomy?

Journal of Clinical Oncology

Volumn 22, Issue 20, 2004, Pages 4103-4108

  Madersbacher, Stephan ^a   Thalmann, George N ^a   Fritsch, Johannes C ^a   Studer, Urs E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ANTINEOPLASTIC AGENT;

ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; HUMAN; MONOTHERAPY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH; ADJUVANT CHEMOTHERAPY; AGED; BLADDER TUMOR; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; EVALUATION; FEMALE; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

AGED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; PROGNOSIS; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 7044263029     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.04.127     Document Type: Article

References (18)

1. Lee JY, Marks JE, Simpson JR: Age as a criterion for eligibility in a lung cancer clinical trial. Am J Clin Oncol 5:449-452, 1982
2. Wittes J, Lakatos E, Black D, et al: Selecting screening criteria for clinical trials: An example from the systolic hypertension in the elderly program. Control Clin Trials 19:121-132, 1999
3. Bjorn M, Brendstrup C, Karlsen S, et al: Consecutive screening and enrollment in clinical trials: The way to representative patient samples? J Card Failure 4:225-230, 1998
4. Canellos GP: Selection bias in trials of transplantation for metastatic breast cancer: Have we picked the apple before it was ripe? J Clin Oncol 15:3169-3170, 1997
5. Winger MJ, Macdonald DR, Schold SC Jr, et al: Selection bias in clinical trials of anaplastic glioma. Ann Neurol 26:531-534, 1989
6. Taylor JM, Withers HR: Influence of selection bias on dose-time analysis: A theoretical investigation. Radiother Oncol 40:259-270, 1996
7. Bhansali MS, Patil PK, Badwe RA, et al: Historical control bias: Adjuvant chemotherapy in esophageal cancer. Dis Esophagus 10:51-54, 1997
8. Studer UE, Bacchi M, Biederman C, et al: Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: Results of a prospective randomized tiral. J Urol 152:81-84, 1994
9. Madersbacher S, Hochreiter W, Burkhard F, et al: Radical cystectomy for bladder cancer today: A homogeneous series without neoadjuvant therapy. J Clin Oncol 21:690-696, 2003
10. Fleming ID, Cooper JS, Henson DE, et al (eds.): AJCC Cancer Staging Manual (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp. 241-243
11. Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 19:666-675, 2001
12. Sternberg CN, Parmar MKB: Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer. J Clin Oncol 19:21-26, 2001 (suppl)
13. Rahman ZU, Frye DK, Buzdar AU, et al: Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 15:3171-3177, 1997
14. Garcia-Carbonero R, Hidalgo M, Paz-Ares L, et al: Patient selection in high-dose chemotherapy trials: Relevance in high-risk breast cancer. J Clin Oncol 15:3178-3184, 1997
15. Robinson D, Woerner MG, Pollack S, et al: Subject selection biases in clinical trials: Data from a multicenter schizophrenia treatment study. J Clin Psychopharmacol 16:170-176, 1996
16. Flanigan RC, Salmon SE, Blumenstein BA, et al: Nephrectomy followed by interferon alpha-2b compared with interferon alpha-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655-1659, 2001
17. Tannock IF: Removing the primary tumour after the cancer has spread. N Engl J Med 345:1699-1700, 2001
18. Liu PY, LeBlanc M, Desai M: False positive rates of randomized phase II designs. Control Clin Trials 20:343-352, 1999